Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-04
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Rotavirus Infection Suppresses Nrf2 Antioxidant Pathways via

    2026-05-18

    Progressive Rotavirus Infection Suppresses Nrf2-Driven Antioxidant Defenses

    Study Background and Research Question

    Rotavirus (RV) is a major pathogen associated with acute gastroenteritis, particularly in infants and young children. Beyond its well-known cytopathic effects, RV infection triggers profound alterations in host cell signaling, especially those governing stress adaptation and redox balance. The nuclear factor erythroid 2-related factor 2 (Nrf2) is a master regulator of the antioxidant response, controlling transcription of multiple cytoprotective genes such as heme oxygenase-1 (HO-1), NAD(P)H quinone dehydrogenase 1, and superoxide dismutase 1. Under homeostatic conditions, Nrf2 is tightly regulated by Keap1 and the Cullin3-based E3 ubiquitin ligase complex, which targets it for rapid proteasomal degradation. The interplay between viral infection and Nrf2-mediated redox regulation, particularly the mechanisms underlying Nrf2 suppression during infection, remains insufficiently characterized. This study specifically investigates how progressive RV infection modulates Nrf2 levels and its transcriptional activity in vitro (Patra et al., 2020).

    Key Innovation from the Reference Study

    The central innovation of the study lies in its temporal dissection of Nrf2 regulation during RV infection. The researchers demonstrate that Nrf2 levels initially rise in response to early oxidative stress but are sharply downregulated as infection progresses. Importantly, they show that this reduction is not solely due to changes in cellular redox status; rather, it is closely linked to enhanced proteasomal degradation mediated by K48-linked ubiquitination. The study further reveals that inhibiting the canonical Cullin3-RING Box1 (Cul3-Rbx1) neddylation pathway—central to Nrf2 turnover—does not restore Nrf2 levels after RV infection, underscoring the complexity and redundancy of ubiquitin-mediated regulation in infected cells (Patra et al., 2020).

    Methods and Experimental Design Insights

    The investigators used a combination of cell culture models infected with the SA11 strain of rotavirus to assess time-dependent changes in Nrf2 expression and activity. Key techniques included Western blotting for Nrf2 protein quantification, immunofluorescence microscopy to evaluate nuclear localization, and qPCR analysis of Nrf2 target gene expression. Pharmacological manipulation was employed to dissect the regulatory mechanisms: antioxidants were used to probe redox sensitivity, while specific inhibitors of the neddylation and proteasome pathways allowed the authors to interrogate post-translational regulation of Nrf2. Crucially, the study examined the effects of both canonical and non-canonical pathways by using agents that stabilized Nrf2 via inhibition of the Keap1-Cul3 axis and by directly blocking proteasome activity. The temporal resolution—monitoring changes at early and late time points post-infection—enabled the identification of distinct phases in Nrf2 regulation.

    Protocol Parameters

    • assay | Western blot for Nrf2 | protein quantification in RV-infected cells | enables detection of dynamic Nrf2 regulation during infection | paper
    • assay | Immunofluorescence microscopy | nuclear localization of Nrf2 | visualizes translocation and nuclear vacuity | paper
    • assay | qPCR for HO-1, NQO1, SOD1 | expression of antioxidant genes | quantifies Nrf2 target gene suppression | paper
    • compound | proteasome inhibitor (e.g., MG132, 10 μM) | post-infection stabilization of Nrf2 | tests dependence on proteasome-mediated degradation | paper
    • compound | neddylation pathway inhibitor (e.g., MLN4924, 0.5–2 μM) | inhibition of Cul3-Rbx1 E3 ligase activity | evaluates role of canonical Nrf2 turnover | workflow_recommendation
    • time course | 0–24 hours post RV infection | kinetic profiling | distinguishes early induction vs. late suppression | paper

    Core Findings and Why They Matter

    The study's main findings are:
    • Biphasic Nrf2 Regulation: Nrf2 is transiently upregulated during the early oxidative burst following RV infection but subsequently undergoes profound downregulation at later stages, independent of continued oxidative stress (Patra et al., 2020).
    • Suppression of Antioxidant Genes: Downregulation of Nrf2 is accompanied by reduced expression of its downstream targets HO-1, NQO1, and SOD1, confirming a functional compromise in the antioxidant defense program.
    • Proteasomal Degradation via Ubiquitination: The loss of Nrf2 is associated with increased K48-linked ubiquitination and is reversible by proteasome inhibition but not by blocking the canonical Cul3-Rbx1 neddylation pathway.
    • Redox-Independent Suppression: Pharmacological restoration of redox balance fails to rescue Nrf2 levels at later infection stages, indicating a redox-independent mechanism for Nrf2 turnover.
    These results shed light on how RV manipulates host cell machinery to evade antioxidant defenses, a strategy likely facilitating its replication and persistence. By revealing that Nrf2 downregulation is mediated through enhanced proteasomal degradation, the study suggests that interventions targeting ubiquitin-proteasome components could restore cellular resilience to oxidative stress during infection.

    Comparison with Existing Internal Articles

    Internal resources extensively cover the pharmacology and research applications of neddylation pathway inhibition, particularly in cancer models. For example, one article outlines how MLN4924, a potent and selective NEDD8-activating enzyme inhibitor, disrupts cullin-RING ligase (CRL) activity, leading to cell cycle arrest and apoptosis in tumor cells (source: product_spec). Similarly, advanced workflows leverage MLN4924 to unravel CRL-mediated ubiquitination in solid tumor models. However, the Patra et al. study uniquely situates the neddylation/ubiquitin-proteasome axis within the context of viral infection and redox biology. While cancer biology research focuses on the consequences of CRL inhibition for tumor growth and survival, this study highlights how viruses may exploit or bypass similar regulatory machinery to suppress host stress responses. The cross-talk between neddylation, ubiquitination, and redox regulation is thus highly relevant for both domains, although direct evidence for neddylation inhibitors in antiviral models remains limited (internal review).

    Why this cross-domain matters, maturity, and limitations

    The mechanistic overlap between neddylation pathway inhibition in cancer and ubiquitin-proteasome modulation in viral infection underscores the potential for translational insights. Both fields are concerned with the turnover of key regulatory proteins (such as Nrf2 or cell cycle regulators) via CRL E3 ligases. Nevertheless, while the therapeutic application of NEDD8-activating enzyme inhibitors like MLN4924 is well established in oncology (product_spec), their use in antiviral strategies remains largely unexplored and should be considered investigational. The present study does not directly test neddylation inhibitors in the context of RV infection, and extrapolation should be approached with caution.

    Limitations and Transferability

    Key limitations of the study include its reliance on in vitro models, which may not fully recapitulate the in vivo complexity of host-virus interactions and immune modulation. The observation that Cul3-Rbx1 inhibition fails to restore Nrf2 levels suggests alternative E3 ligases or regulatory circuits are at play, but these remain to be identified. Additionally, while proteasome inhibition restores Nrf2, such broad inhibition is not feasible therapeutically due to toxicity. Transferability to other viral models or disease settings (such as cancer) will require further validation, particularly regarding the specificity and safety of targeting the ubiquitin-proteasome system to modulate Nrf2 and related stress pathways.

    Research Support Resources

    Researchers investigating the molecular mechanisms of protein turnover—including neddylation pathway inhibition and CRL-mediated ubiquitination—can leverage selective tools such as MLN4924 (SKU B1036) to dissect pathway contributions in cancer biology and potentially other models. MLN4924 is a validated NEDD8-activating enzyme inhibitor with robust selectivity for the neddylation system, and its application in experimental protocols is well documented in the literature (product_spec). For detailed protocols, troubleshooting, and translational insights, refer to internal resources such as the MLN4924 protocol guide and the neddylation frontier review.